We previously reported that a 150 mg or higher daily dose is necessary for treatment of pulmonary aspergillosis with micafungin (MCFG) alone in patients with blood diseases. Since a delay in the treatment of pulmonary aspergillosis has a major influence on patient survival, clarification of the effective blood concentration of MCFG enables rapid treatment. Establishment of an appropriate dose is also useful for reducing the risk of adverse effects, such as MCFG-induced impairment of liver function. Aiming for the rapid and safe treatment of pulmonary aspergillosis, we established new clinical diagnostic criteria of mycosis and MCFG therapeutic effect judgment criteria, and investigated the effective blood concentration of MCFG for mycosis. The blood trough level of MCFG in patients with blood diseases at each clinical improvement rating of pulmonary aspergillosis was 5.23؎2.44 m mg/ml in markedly improved cases, 4.08؎2.63 m mg/ml in improved cases, and 3.45؎1.63 m mg/ml in successfully prevented cases, showing no significant difference among the 3 groups. Based on this finding, it is advisable to target a 5 m mg/ml or higher blood trough level of MCFG in establishing the dose for aspergillosis in patients with blood diseases.
Micafungin (MCFG) is a novel drug with a different action mechanism from existing antifungal agents, and its clinical efficacy is expected. MCFG exhibits a wide antifungal spectrum against Candida and Apergillus species in vitro by inhibiting biosynthesis of the major fungal cell wall component, 1,3-b-D-glucan. 1, 2) Its superior transfer to the lung 3) may be highly effective for prevention and treatment of pulmonary mycosis. Clinically, MCFG is particularly important for treatment of pulmonary aspergillosis, which is problematic in patients with blood diseases.
We previously reported that a 150 mg or higher daily dose is necessary for treatment of pulmonary aspergillosis with MCFG alone for patients with blood diseases from our clinical experience. 4, 5) However, we often encounter cases in which no therapeutic effect is obtained despite MCFG being administered at a sufficient dose, and a dose increase of MCFG or switch to other drugs is necessary. Moreover, no clear basis for dose adjustment is available for MCFG dose reduction in patients with severe impairment of renal or liver function. If the blood MCFG level does not reach the therapeutic level and delays treatment of pulmonary aspergillosis, it may have a major influence on patient survival. Clarification of the effective blood concentration of MCFG by evaluating its clinical effect enables rapid and accurate treatment. Establishment of an appropriate dose is also useful for reducing the risk of adverse effects, such as MCFG-induced impairment of liver function.
Aiming for the rapid and safe treatment of pulmonary aspergillosis, we established new clinical diagnostic criteria of mycosis and a clinical improvement rating associated with MCFG administration, and investigated the effective blood concentration of MCFG for mycosis. The effective blood trough level of MCFG for pulmonary aspergillosis, which has not previously been established, was determined. The findings promoted rapid and safe treatment of pulmonary aspergillosis in patients with blood diseases.
MATERIALS AND METHODS

Subjects
The subjects were 36 patients admitted to the Nagano Red Cross Hospital Department of First Internal Medicine (Hematology) between February 2003 and October 2004, who agreed to the measurement of blood MCFG concentration, and gave written informed consent (by the patients or their families). When MCFG treatment was re-initiated after a withdrawal, and the objective of MCFG treatment was changed due to the disease condition, the former and latter treatments in the patient were handled as different cases.
Blood Sampling The blood half-life of MCFG has been clarified to be about 15 h by hemodynamic investigation. 6) Since the drug level reaches a steady state within about 4 times the half-life, the MCFG level is estimated to reach a steady state after about 60 h. 7) Thus, as a rule, blood was collected at a trough level after day 3 of administration, at which time the steady state was reached. Reduction of the patient's physical burden was prioritized in blood sampling. The objective of blood sampling was not limited to blood MCFG measurement, and a portion of blood collected for the conventional laboratory test was used as a sample. The blood level was measured at only a single time point in the steady state.
Explanation and Informed Consent The study was explained to the patients and their families, and informed consent was obtained with consideration of protecting patients' rights in accordance with the Helsinki Declaration. The utilization of blood samples for only this study, and not for any other purpose, was also explained, and written informed consent was obtained from the patients or their families. This study was approved by the Ethics Committee, consisting of 20 members including full-time physicians, pharmacists, and nurses of the Nagano Red Cross Hospital and external persons of learning and experience (lawyers).
New Diagnostic Criteria of Mycosis
Although it is considered desirable to use the international criteria, European Organization for Research and Treatment of Cancer (EORTC), these diagnostic criteria require an invasive test. 8) Since our hospital is not allowed to perform invasive tests for clinical studies, we established original diagnostic criteria, in which patients are classified into 3 categories: clinically diagnosed cases, suspected cases, and cases treated for prevention, based on the diagnosis made by attending physicians when MCFG administration was decided (Table 1) .
MCFG-Associated Clinical Improvement Rating and Effective Blood Concentration
The improvement of clinical symptoms was rated at completion of MCFG administration as per the 5 categories shown in Table 2 on comparison with the clinical symptoms before initiation of administration: markedly improved, improved, unchanged, aggravated, and not evaluated. Cases treated for prevention of fungal infection were rated in 2 categories: successful and unsuccessful. Successful prevention was defined as completion of MCFG administration without clinical diagnosis of new fungal infection or a shift to a suspected case under MCFG treatment alone. 9) Attending physicians comprehensively determined the clinical improvement rating referring to concomitant drugs administered during the MCFG administration period, highest daily body temperature, C reactive protein (CRP) level, white blood cell count, neutrophil count, imaging diagnosis, fungal culture/identification, and serological test. The MCFG level measured on the nearest day to the judgment of the clinical improvement rating was regarded as the effective blood concentration.
Determination of MCFG in Plasma Preparation of the Solutions A standard solution of MCFG and a solution containing an internal standard substance (IS), FR195743, analogous structure of MCFG, were supplied by Fujisawa Pharmaceutical Co., Ltd. MCFG was dissolved in ethanol at a concentration of 100 mg/ml, and the standard stock solution thus prepared was stored at Ϫ20°C. The IS was dissolved in 0.02 mol/l potassium dihydogenphosphate/acetonitrile (50/50, v/v) at a concentration of 100 mg/ml, and the IS stock solution thus prepared was stored at 4°C. The standard stock solution was diluted with ethanol to make standard working solutions at a concentration of 25, 10, 2.5, 1, 0.25, and 0.05 mg/ml, respectively. The IS stock solution was diluted with 0.02 mol/l potassium dihydogenphosphate/acetonitrile (50/50, v/v) to make an IS working solution at a concentration of 0.25 mg/ml.
Determination of Plasma MCFG by the Internal Standard Method Plasma samples (50 ml) from a healthy volunteer without MCFG treatment was transferred to a plastic microcentrifuge tube, and 50 ml of the standard working solution, 50 ml of the IS working solution, 50 ml of acetonitrile were added, and then mixed vigorously for 10 s. These solutions were centrifuged at 10000 rpm for 1 min, and 100 ml aliquot of the supernatant was mixed with 200 ml of 0.02 mol/l potassium dihydogenphosphate/acetonitrile (50/50, v/v). The mixture was filtered with a filter membrane (Millex-LG, 0.45 mm), and 75 ml aliquot of the filtrate was determined by high performance liquid chromatography (HPLC). The calibration curve was obtained by the peak height ratio of MCFG vs. the IS. Plasma samples (50 ml) from the patients treated with MCFG was determined by the internal standard method. Linearity of the calibration curve is very well, and a correlation coefficient usually shows over 0.999. HPLC Analytical Conditions HPLC was performed using a TSK gel ODS-80Ts column (4.6 mmϫ150 mm) as an analytical column and a TSK guard gel ODS-80Ts (3.2 mm ϫ15 mm) as a guard column. The mobile phase of 0.02 mol/l potassium dihydogenphosphate/acetonitrile (56/44, v/v) was pumped at a flow rate of 1 ml/min, and column temperature was kept at 50°C. Fluorometric detection was carried out with a RF-530 fluorometer (Shimadzu) at an excitation wavelength of 273 nm and a fluorescence wavelength of 464 nm. Under the condition, retention times of MCFG and the IS were 8.6 min and 15.4 min, respectively.
Statistical Analysis We used the SPSS ® 14.0J software for Windows ® .
RESULTS
Patient Background
The primary disease of the 36 patients was acute myeloblastic leukemia (AML) in 16, acute lymphoblastic leukemia (ALL) in 3, myelodysplastic syndrome (MDS) in 4, non-Hodgkin's lymphoma (NHL) in 9, Prevention of fungal infection is necessary because fungal infection is very likely to occur due to the pathological condition during treatment of primary disease, and if it occurs, it may become serious.
Initiation of MCFG administration was decided by attending physicians, and the patients were divided into the above 3 groups on the basis of the diagnosis. At completion of administration, the outcomes were compared with clinical symptoms before drug administration, and rated as per the 5 categories of the above criteria.
multiple myeloma (MM) in 1, aplastic anemia (AA) in 2, and myelofibrosi (MF) in 1 ( Table 3) . Diagnosis and Clinical Improvement Rating of the 36 patients, pulmonary aspergillosis was clinically diagnosed in 7, fungal infection was suspected in 9, and 20 patients received preventive administration. The clinical improvement rating was 'markedly improved' in 3 and 'improved' in 4 of the 7 clinically diagnosed patients, and 'markedly improved' in 2 and 'improved' in 7 of the 9 patients suspected with fungal infection. Prevention was successful in all 20 patients treated for prevention (Table 3) .
Administration Method, Dose, and Duration of Administration MCFG was administered once a day in all patients. The drug was dissolved in 100 ml of physiological saline, and administered by intravenous drip infusion for 1 h. The daily dose of MCFG was 96.4Ϯ38.8, 111.0Ϯ29.1, and 97.5Ϯ36.1 mg in the patients clinically diagnosed with pulmonary aspergillosis, suspected with fungal infection, and treated for prevention, respectively. The duration of MCFG administration was 43.0Ϯ17.1, 15.6Ϯ7.0, and 25.0Ϯ20.1 d, respectively. The total dose of MCFG was 4157Ϯ1802, 1969Ϯ1502, and 2650Ϯ2514 mg, respectively, showing that the duration of administration was longer and the total dose was higher in the patients clinically diagnosed with pulmonary aspergillosis than in the patients suspected with fungal infection and treated for prevention (Table 3) . (Each data represents the meanϮS.D.) Laboratory Test Findings In the patients with pulmonary aspergillosis (Fig. 1) , body temperature was 38.4Ϯ 0.8°C before administration, and decreased to 36.8Ϯ0.6°C after administration (pϭ0.0049), CRP decreased from 6.95Ϯ5.88 to 1.62Ϯ2.05 mg/dl (pϭ0.0082), and b-D-glucan decreased from 9.73Ϯ13.69 to 4.50Ϯ2.16 pg/ml (no significant difference). In the patients suspected with fungal infection (Fig. 2) , body temperature decreased from 38.9Ϯ0.5°C to 37.2Ϯ1.0°C after administration (pϭ0.0061), CRP decreased from 10.55Ϯ6.38 to 2.56Ϯ3.57 mg/dl (pϭ0.0062), and b-D-glucan decreased from 8.82Ϯ5.13 to 3.94Ϯ0.64 pg/ml (no significant difference). In the patients treated for prevention of fungal infection (Fig. 3) , body temperature decreased from 38.0Ϯ1.2°C to 37.2Ϯ0.7°C after administration (pϭ0.0009), CRP decreased from 5.80Ϯ6.97 to 2.93Ϯ4.01 mg/dl (pϭ0.0125), and b-D-glucan decreased from 4.53Ϯ2.62 to 3.68Ϯ1.03 pg/ml (no significant difference). In all 3 groups, body temperature and CRP level were significantly improved, but no significant change was noted in b-D-glucan. The values of tests performed immediately after the completion of MCFG administration were adopted as the values after administration. (Each data represents the meanϮS.D. and were statistically evaluated using T test.)
Blood Concentration The blood trough concentration of MCFG in each category of the clinical diagnostic criteria (Fig. 4) was 4 .24Ϯ2.80, 4.41Ϯ2.55, and 3.45Ϯ1.63 mg/ml in the patients clinically diagnosed with pulmonary aspergillosis, suspected with fungal infection, and treated for prevention, respectively, showing no significant difference among the 3 groups. Similarly, the blood trough concentration of MCFG in the clinical improvement rating (Fig. 5) was 5.23Ϯ2.44, 4.08Ϯ2.63, and 3.45Ϯ1.63 mg/ml in the markedly improved, improved, and successfully prevented cases, respectively, showing no significant difference among the 3 groups. (Each data represents the meanϮS.D. and were statistically evaluated using Tukey's HDS test.)
DISCUSSION
Following comprehensive judgment of the clinical diagnosis based on the criteria, clinical improvement rating, and blood trough MCFG concentration, it may be desirable to target a blood trough MCFG level of about 4 mg/ml in establishing the dose for pulmonary aspergillosis. In consideration of the blood trough MCFG level of 5.23Ϯ2.44 mg/ml in the markedly improved cases, a 5 mg/ml or higher dose may be necessary for severe cases. The protein-binding rate of MCFG is high, and changes in the free MCFG level may affect the clinical improvement rating and determination of the 1888 Vol. 29, No. 9 (4) improved (7) prevented (20) AML: acute myeloblastic leukemia, MDS: myelodysplastic syndrome, AA: aplastic anemia, ALL: acute lymphoblastic leukemia, NHL: non-Hodgkin's lymphoma, MM: multiple myeloma, MF: myelofibrosis, T. Bil: total serum bilirubin level, Ccr: serum creatinine clearance level, Alb: serum albumin level. Body temperature decreased from 38.9Ϯ0.5°C to 37.2Ϯ1.0°C after administration (pϭ0.0061), CRP decreased from 10.55Ϯ6.38 to 2.56Ϯ3.57 mg/dl (pϭ0.0062), and b-D-glucan decreased from 8.82Ϯ5.13 to 3.94Ϯ 0.64 pg/ml (no significant difference). Each data represents the meanϮS.D. and were statistically evaluated using T test. effective blood level. However, no significant differences were noted in the protein-binding or unbound rate between patient groups in studies comparing elderly and non-elderly subjects, and healthy subjects and patients with moderately impaired liver or renal function, suggesting that there were no significant differences in the protein-binding or unbound rate among patient groups in this study. 10) In patients for whom deep mycosis is problematic, a delay in the treatment of pulmonary aspergillosis is very likely to have a major influence on survival, particularly in patients with blood diseases. Measurement of the blood MCFG concentration and establishment of a dose targeting a 5 mg/ml or higher blood trough MCFG concentration for severe cases may enable rapid treatment. As described above, we have established a daily dose of 150 mg or higher for the treatment of pulmonary aspergillosis with MCFG alone from our clinical experience. 4, 5) However, the results of blood level measurement in this study revealed that a dose lower than 150 mg may be sufficiently effective for some cases when a blood trough level of 4-5 mg/ml is targeted. Establishment of an appropriate dose based on the blood level, not from experience, may reduce the risk of adverse effects, such as impairment of liver function, which is often reported. 11) As for treatment of Candida infection, we encountered one patient in this study (unpublished), and it was suggested that a sufficient effect may be obtained at a lower concentration than that for aspergillosis. In the clinical findings, body temperature and CRP were sufficiently improved, but the decrease in b-D-glucan was small. Measurement of b-D-glucan is an assistive diagnosis of fungal infection, and its diagnostic value is not necessarily high, but its positivity can be utilized for judgment of drug effects, and the test is frequently used in clinical practice. Thus, b-D-glucan was added to the laboratory test items, but no significant change was noted after MCFG administration. As reasons for the absence of change, generally, the sensitivity of b-D-glucan measurement is about 90% in Candida infection and about 60-80% in aspergillosis, b-D-glucan release markedly varies depending on fungal species and pathology, particularly in Aspergillus infection, making evaluation of the sensitivity difficult, 12, 13) and b-Dglucan was measured before and after MCFG administration in fewer patients.
The blood MCFG concentration was measured at the trough point in all patients. In basic studies of the post-antifungal effect (PAFE) of antifungal agents, MCFG exhibited PAFE for Candida infection, but not for Aspergillus infection. [14] [15] [16] These reports indicate the significance of the blood trough concentration of MCFG for aspergillosis. However, in humans, it is unclear whether the clinical efficacy of MCFG is dependent on the peak or trough level. Thus, it is necessary to investigate the degree of clinical importance of the trough level in an increased number of cases when the blood MCFG level is measured.
We may encounter cases in which the therapeutic effect is low despite MCFG being administered at a sufficient dose in severe cases (unpublished). For such cases, MCFG and voriconazole (VRCZ) combination therapy is expected to be effective. 17, 18) However, VRCZ exhibits various interactive effects, and thus, combination with other drugs including antifungal agents should be carefully implemented. Since it is desirable to measure the blood concentration during administration of VRCZ, measurement of blood concentrations of both MCFG and VRCZ may be necessary for treatment of intractable deep mycosis with concomitant MCFG and VRCZ.
CONCLUSION
For administration of MCFG for severe pulmonary aspergillosis, it is advisable to target a 5 mg/ml or higher trough blood level of MCFG in establishing the dose in patients with blood diseases. It is necessary to investigate the degree of clinical importance of the measurement of the blood trough level of MCFG. The blood trough MCFG concentrations were 4.24Ϯ2.80, 4.41Ϯ2.55, and 3.45Ϯ 1.63 mg/ml in the patients clinically diagnosed with pulmonary aspergillosis, suspected with fungal infection, and treated for prevention of fungal infection, respectively, showing no significant difference among the 3 groups. Each data represents the meanϮS.D. and were statistically evaluated using Tukey's HDS test.
Fig. 5. Blood MCFG Concentration in Clinical Improvement Rating
The blood trough concentration of MCFG in the clinical improvement rating was 5.23Ϯ2.44, 4.08Ϯ2.63, and 3.45Ϯ1.63 mg/ml in the markedly improved, improved, and successfully prevented cases, respectively, showing no significant difference among the 3 groups. Each data represents the meanϮS.D. and were statistically evaluated using Tukey's HDS test.
